試す 金 - 無料
Eschewing Myopic Attitude Towards Eye Health
BioSpectrum Asia
|July 2022
Direct costs of myopia in Asia alone have been estimated at $328 billion every year, with an additional $244 billion in productivity losses associated with myopia.
In many East Asian countries, myopia is a major public health concern that affects between 80 and 90 per cent of high school graduates, of which about 10 to 20 per cent have sight-threatening pathologic myopia. Thus, early intervention is crucial in the control of myopia and the onus is to be equally distributed between the stakeholders of the eye healthcare ecosystem. Studie have shown that the increased intensity of educational pressures in young children has coincided with the rapid rise in myopia cases in Asian countries in recent decades. Let's explore the available early interventions that could effectively tackle the rising incidents of myopia, especially in the young.
Uncorrected myopia remains the leading cause of distance vision impairment globally, and its rising prevalence could cost billions of dollars in lost productivity in the coming decades. A hallmark study by the Brien Holden Vision Institute (BHVI) in Australia predicts that by 2050, over half the world's population or 52 per cent will be myopic.
Direct costs of myopia in Asia alone have been estimated at $328 billion every year, with an additional $244 billion in productivity losses associated with myopia.
Studies have shown the increased intensity of educational pressures in young children has coincided with the rapid rise in myopia cases in Asian countries in recent decades. In many East Asian countries, myopia is a major public health concern that affects between 80 and 90 per cent of high school graduates, of which about 10 to 20 per cent have sight-threatening pathologic myopia.
In particular, with quarantine practices in place during the onset of COVID-19 and children attending online classes over electronic devices, the rise in myopia has been sharp. According to a recent study, more children have developed myopia as an unexpected side-effect of the pandemic.
このストーリーは、BioSpectrum Asia の July 2022 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
BioSpectrum Asia からのその他のストーリー
BioSpectrum Asia
Waters launches charge detection mass spectrometry technology
US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia
The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
WHO strengthens coordination for NTD programmes and supply chain delivery
The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
All-in-one coronavirus vaccines to save millions in future pandemics
A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
NTU in Singapore introduces Master of Science course in Chinese Medicine
From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
ProSpecBio launches Activin-A recombinant protein for brain injury research
Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
PAHO publishes guide for designing AI instructions in public health
The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Prerna launches India's first MicroRNA based blood test for breast cancer screening
Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan
Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.
1 min
BioSpectrum Asia Nov 2025
Translate
Change font size
